Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2491-2497

  Yamamoto, Suguru ^a   Zuo, Yiqin ^a   Ma, Ji ^a   Yancey, Patricia G ^a   Hunley, Tracy E ^a   Motojima, Masaru ^b   Fogo, Agnes B ^a   Linton, MacRae F ^a   Fazio, Sergio ^a   Ichikawa, Iekuni ^a   Kon, Valentina ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

AST 120; atherosclerosis; charcoal adsorbent; necrotic lesion; renal ablation

Indexed keywords

APOLIPOPROTEIN E; AST 120; CHOLESTEROL; COLLAGEN; CREATININE; INDICAN; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MECHANISM; FEMALE; MACROPHAGE; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CARBON; CHARCOAL; CHEMOKINE CCL2; FEMALE; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-1BETA; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959368409     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq759     Document Type: Article

References (43)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42:1050-1065 (Pubitemid 37413751)
2. Elsayed EF, Tighiouart H, Griffith J et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007;167:1130-1136 (Pubitemid 46919815)
3. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004;164:659-663 (Pubitemid 38392981)
4. Koren MJ, Davidson MH, Wilson DJ et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 2009;53:741-750
5. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-1407
6. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979 (Pubitemid 27152782)
7. Sanaka T, Sugino N, Teraoka S et al. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988;12:97-103
8. Owada A, Nakao M, Koike J et al. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study. Kidney Int Suppl 1997;63:S188-S190 (Pubitemid 28020467)
9. Schulman G, Agarwal R, Acharya M et al. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006;47:565-577
10. Aoyama I, Shimokata K, Niwa T. An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats. Nephron 2002;92:635-651
11. Nakagawa N, Hasebe N, Sumitomo K et al. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol 2006;26:455-461 (Pubitemid 44971736)
12. Miyazaki T, Aoyama I, Ise M et al. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 2000;15:1773-1781
13. Akizawa T, Asano Y, Morita S et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009;54:459-467
14. Ueda H, Shibahara N, Takagi S et al. AST-120 treatment in predialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008;30:856-860
15. Barreto FC, Barreto DV, Liabeuf S et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:1551-1558
16. Ma J, Weisberg A, Griffin JP et al. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 2006;69:1064-1072 (Pubitemid 43372182)
17. Fazio S, Major AS, Swift LL et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 2001;107:163-171 (Pubitemid 32096832)
18. Ayabe N, Babaev VR, Tang Y et al. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis 2006;184:312-321 (Pubitemid 43049715)
19. Owada S, Goto S, Bannai K et al. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 2008;28:446-454 (Pubitemid 351501611)
20. Seimon TA, Wang Y, Han S et al. Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest 2009;119:886-898
21. Westenfeld R, Schafer C, Smeets R et al. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant 2007;22:1537-1546 (Pubitemid 47073751)
22. Ma LJ, Fogo AB. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 2003;64:350-355 (Pubitemid 36714190)
23. Bro S, Bentzon JF, Falk E et al. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003;14:2466-2474 (Pubitemid 37169332)
24. Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-2610 (Pubitemid 39628581)
25. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
26. Parekh RS, Plantinga LC, Kao WH et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int 2008;74:1335-1342
27. Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005;68:766-772 (Pubitemid 43323132)
28. Fujii H, Nishijima F, Goto S et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009;24:2089-2095
29. Suganuma E, Zuo Y, Ayabe N et al. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J Am Soc Nephrol 2006;17:433-441
30. Suganuma E, Babaev VR, Motojima M et al. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. J Am Soc Nephrol 2007;18:2311-2319 (Pubitemid 47203847)
31. Tumur Z, Shimizu H, Enomoto A et al. Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol 2010;31:435-441
32. Ito S, Osaka M, Higuchi Y et al. Indoxyl sulfate induces leukocyteendothelial interactions through upregulation of E-selectin. J Biol Chem 2010;285:38869-38875
33. Thorp E, Cui D, Schrijvers DM et al. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/-mice. Arterioscler Thromb Vasc Biol 2008;28:1421-1428
34. Yancey PG, Blakemore J, Ding L et al. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler Thromb Vasc Biol 2010;30:787-795
35. Welch CL, Sun Y, Arey BJ et al. Spontaneous atherothrombosis and medial degradation in Apoe-/-, Npc1-/-mice. Circulation 2007;116:2444-2452 (Pubitemid 350145079)
36. Zuo Y, Yancey P, Castro I et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol 2009;29:1277-1282
37. Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol 2010;30:177-181
38. Ivanovski O, Szumilak D, Nguyen-Khoa T et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005;67:2288-2294 (Pubitemid 41623388)
39. Phan O, Ivanovski O, Nguyen-Khoa T et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005;112:2875-2882 (Pubitemid 41641683)
40. Massy ZA, Ivanovski O, Nguyen-Khoa T et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005;16:109-116 (Pubitemid 43073162)
41. Phan O, Ivanovski O, Nikolov IG et al. Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant 2008;23:82-90 (Pubitemid 351767422)
42. Takahashi A, Takase H, Toriyama T et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 2006;21:2507-2512 (Pubitemid 44644524)
43. Suzuki H, Kanno Y, Sugahara S et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008;52:501-506